EJA:心脏手术中血栓弹性描记法评价的两种氨甲环酸剂量对纤维蛋白溶解的影响:一项随机对照研究

2014-08-18 MedSci小编 MedSci原创

心脏手术中凝血酸用于减少出血和输血的情况。然而,基于药代动力学,以最佳抑制纤维蛋白溶解的药物剂量还处于未知。考虑到高剂量凝血酸会导致癫痫发作,因此寻找最佳低剂量方案是十分有必要的。这项双盲随机对照先导试验,便是为了对比两个给药方案与安慰剂,对纤溶的临床作用。试验选取33名需要体外循环的心脏手术病人,随机分为3组。高剂量组: 一次性注射30 mg/ kg氨甲环酸,之后连续注射每小时

心脏手术中凝血酸用于减少出血和输血的情况。然而,基于药代动力学,以最佳抑制纤维蛋白溶解的药物剂量还处于未知。考虑到高剂量凝血酸会导致癫痫发作,因此寻找最佳低剂量方案是十分有必要的。项双盲随机对照先导试验,便是为了对比两个给药方案与安慰剂,对纤溶的临床作用。

试验选取33名需要体外循环的心脏手术病人,随机分为3组。高剂量组 一次性注射30 mg/ kg氨甲环酸,之后连续注射每小时16mg /kg−1 h−1,低剂量组 一次性注射5 mg/ kg氨甲环酸,之后连续注射5毫克公斤,5 mg kg−1 h−1 以及 安慰剂组氯化钠。

主要评估血栓和D-二聚体,以此来评价纤维蛋白溶解程度。次要终点是失血,输血需求和副作用。 

LY30>7.5%且在任何群体体外循环后没有观察到血栓则定义为显著纤溶。在注射鱼精蛋白后,高剂量组和安慰剂组对比,LY30差异为 0.7 [95% confidence interval (95% CI) –0.04 to 1.4];低剂量组与安慰剂相比,LY30差异为 0.78 (95% CI 0.02 to 1.5),高低两组LY30差异为–0.08 (95% CI –0.82 to 0.66) 。安慰剂组的D-二聚体显著增加,但出血或输血的要求没有明显差异。 

在这个剂量考察研究,两种剂量的氨甲环酸和安慰剂之间的纤维蛋白溶解无明显差异。仍需更大动力的研究。

原始出处:

Faraoni D1, Cacheux C, Van Aelbrouck C, Ickx BE, Barvais L, Levy JH.Effect of two doses of tranexamic acid on fibrinolysis evaluated by thromboelastography during cardiac surgery: A randomised, controlled study.Eur J Anaesthesiol. 2014 Sep;31(9):491-8. doi: 10.1097/EJA.0000000000000051.


版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1997232, encodeId=8dca199e23210, content=<a href='/topic/show?id=cc04e727535' target=_blank style='color:#2F92EE;'>#纤维蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77275, encryptionId=cc04e727535, topicName=纤维蛋白)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0ad8182, createdName=axin009, createdTime=Mon May 18 06:15:00 CST 2015, time=2015-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1775271, encodeId=af9f1e75271d0, content=<a href='/topic/show?id=937d46650bf' target=_blank style='color:#2F92EE;'>#对照#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46650, encryptionId=937d46650bf, topicName=对照)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8ae138776909, createdName=amyloid, createdTime=Tue Jul 14 17:15:00 CST 2015, time=2015-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2038265, encodeId=fcdb203826583, content=<a href='/topic/show?id=167c984525d' target=_blank style='color:#2F92EE;'>#随机对照研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98452, encryptionId=167c984525d, topicName=随机对照研究)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Fri May 08 22:15:00 CST 2015, time=2015-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1444097, encodeId=bce1144409e4d, content=<a href='/topic/show?id=3d9291459d1' target=_blank style='color:#2F92EE;'>#评价#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91459, encryptionId=3d9291459d1, topicName=评价)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1fee5134542, createdName=huagfeg, createdTime=Wed Aug 20 00:15:00 CST 2014, time=2014-08-20, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1997232, encodeId=8dca199e23210, content=<a href='/topic/show?id=cc04e727535' target=_blank style='color:#2F92EE;'>#纤维蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77275, encryptionId=cc04e727535, topicName=纤维蛋白)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0ad8182, createdName=axin009, createdTime=Mon May 18 06:15:00 CST 2015, time=2015-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1775271, encodeId=af9f1e75271d0, content=<a href='/topic/show?id=937d46650bf' target=_blank style='color:#2F92EE;'>#对照#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46650, encryptionId=937d46650bf, topicName=对照)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8ae138776909, createdName=amyloid, createdTime=Tue Jul 14 17:15:00 CST 2015, time=2015-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2038265, encodeId=fcdb203826583, content=<a href='/topic/show?id=167c984525d' target=_blank style='color:#2F92EE;'>#随机对照研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98452, encryptionId=167c984525d, topicName=随机对照研究)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Fri May 08 22:15:00 CST 2015, time=2015-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1444097, encodeId=bce1144409e4d, content=<a href='/topic/show?id=3d9291459d1' target=_blank style='color:#2F92EE;'>#评价#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91459, encryptionId=3d9291459d1, topicName=评价)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1fee5134542, createdName=huagfeg, createdTime=Wed Aug 20 00:15:00 CST 2014, time=2014-08-20, status=1, ipAttribution=)]
    2015-07-14 amyloid
  3. [GetPortalCommentsPageByObjectIdResponse(id=1997232, encodeId=8dca199e23210, content=<a href='/topic/show?id=cc04e727535' target=_blank style='color:#2F92EE;'>#纤维蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77275, encryptionId=cc04e727535, topicName=纤维蛋白)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0ad8182, createdName=axin009, createdTime=Mon May 18 06:15:00 CST 2015, time=2015-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1775271, encodeId=af9f1e75271d0, content=<a href='/topic/show?id=937d46650bf' target=_blank style='color:#2F92EE;'>#对照#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46650, encryptionId=937d46650bf, topicName=对照)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8ae138776909, createdName=amyloid, createdTime=Tue Jul 14 17:15:00 CST 2015, time=2015-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2038265, encodeId=fcdb203826583, content=<a href='/topic/show?id=167c984525d' target=_blank style='color:#2F92EE;'>#随机对照研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98452, encryptionId=167c984525d, topicName=随机对照研究)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Fri May 08 22:15:00 CST 2015, time=2015-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1444097, encodeId=bce1144409e4d, content=<a href='/topic/show?id=3d9291459d1' target=_blank style='color:#2F92EE;'>#评价#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91459, encryptionId=3d9291459d1, topicName=评价)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1fee5134542, createdName=huagfeg, createdTime=Wed Aug 20 00:15:00 CST 2014, time=2014-08-20, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1997232, encodeId=8dca199e23210, content=<a href='/topic/show?id=cc04e727535' target=_blank style='color:#2F92EE;'>#纤维蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77275, encryptionId=cc04e727535, topicName=纤维蛋白)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0ad8182, createdName=axin009, createdTime=Mon May 18 06:15:00 CST 2015, time=2015-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1775271, encodeId=af9f1e75271d0, content=<a href='/topic/show?id=937d46650bf' target=_blank style='color:#2F92EE;'>#对照#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46650, encryptionId=937d46650bf, topicName=对照)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8ae138776909, createdName=amyloid, createdTime=Tue Jul 14 17:15:00 CST 2015, time=2015-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2038265, encodeId=fcdb203826583, content=<a href='/topic/show?id=167c984525d' target=_blank style='color:#2F92EE;'>#随机对照研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98452, encryptionId=167c984525d, topicName=随机对照研究)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Fri May 08 22:15:00 CST 2015, time=2015-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1444097, encodeId=bce1144409e4d, content=<a href='/topic/show?id=3d9291459d1' target=_blank style='color:#2F92EE;'>#评价#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91459, encryptionId=3d9291459d1, topicName=评价)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1fee5134542, createdName=huagfeg, createdTime=Wed Aug 20 00:15:00 CST 2014, time=2014-08-20, status=1, ipAttribution=)]
    2014-08-20 huagfeg

相关资讯

华西完成高龄高难度心脏手术

近日,95岁高龄的乐山籍老人陈宗虞在华西医院成功接受抗心衰起搏器安置术,2013年12月31日下午,恢复状况良好的他康复出院,成为全世界有文献资料记载的年龄最大抗心衰起搏器安装者。 2013年8月31日凌晨,此前身体状况一直不错的陈宗虞突感呼吸困难,说话很吃力,,前往华西医院进行治疗,“病人的心脏病导致了心脏功能下降,从而引起心力衰竭,出现心累气紧现象。”心内

Am Heart J:SIRS研究将明确预防性激素是否适用于心脏手术患者

对于需行心肺分流的心脏手术患者,正在实施的加拿大SIRS研究将有助于明确预防性应用激素的安全性和有效性。论文于3月3日在线发表于《美国心脏杂志》(Am Heart J)。 此项研究计划纳入7500在心肺分流情况下接受心脏手术的EuroSCORE升高患者,并随即给予甲强龙或安慰剂治疗。主要转归为30天全因死亡,次要转归由30天内死亡、心梗、卒中、肾衰或呼吸衰竭组成。其他

我国自主研发心脏手术系统攻克世界难题

中国医学科学院阜外心血管病医院院长、中国工程院院士胡盛寿及外科管委会主任王巍领衔的团队,采用我国自主研发的瓣膜植入系统,为两名高龄高危心脏病患者成功实施了“经心尖微创主动脉瓣植入术(TAVI)”,且不开胸、心脏不停跳。这一世界领先技术,使过去无法可医的患者得到了彻底治疗,重获“生机”。 “主动脉瓣狭窄或关闭不全是中老年常见心脏病,严重主动脉瓣病变最终将导致心衰。”胡盛寿指出,一般来说,出现症状后的

JAMA:非心脏手术围手术期使用β-受体阻滞剂或可降低患者死亡率

非心脏手术围手术期应用β-受体阻滞剂治疗的有效性仍存在争议。美国圣弗朗西斯科麻醉医学中心Martin J. London博士及其同事对此进行了深入研究,旨在明确非心脏手术早围手术期使用β-受体阻滞剂治疗与术后30天结局之间的关系。他们的研究发现,对于接受非心脏手术、非血管性手术的倾向性得分匹配的人群来说,围手术期使用β-受体阻滞剂可引起存在2项或更多项改良心脏风险指数因素的患者30天全因死亡率减少

Heart:房颤患者接受心脏手术同时行消融治疗安全有效

澳大利亚和比利时学者对接受心脏手术治疗的心房颤动患者同时进行外科消融治疗与不进行外科消融的临床转归情况进行了随机对照研究(RCT)的荟萃分析,结果表明,患者在接受心脏手术的同时进行外科消融治疗在恢复其窦性心律的方面是安全且有效的。研究论文3月20日在线发表于《心脏》(Heart)。 研究者对6个数据库进行了电子检索,鉴别了所有对比了心房颤动患者接受心脏手术的同时进行外科消融和非消融相关的RCT研

Circulation:右美托咪啶可改善心脏手术患者预后

据胸外科医师协会报告,心脏瓣膜术和冠脉搭桥术术后主要并发症发生率高达30%。其主要并发症有术后谵妄、感染、急性肾衰以及包括永久性和短暂性脑卒中、昏迷、围手术期心梗、心脏传导阻滞和心脏骤停在内的主要心脑血管不良事件,有超过50%的不良事件为心血管事件。这些不良事件的原因是多方面的,其中一个主要因素是手术应激反应导致体内肾上腺素和去甲肾上腺素增加造成心肌氧供需失衡及心肌缺血。右美托咪啶(α- 2受体激